Boston Scientific Corporation (LON:0HOY)
| Market Cap | 104.74B |
| Revenue (ttm) | 14.39B |
| Net Income (ttm) | 2.08B |
| Shares Out | n/a |
| EPS (ttm) | 1.39 |
| PE Ratio | 50.44 |
| Forward PE | 28.56 |
| Dividend | n/a |
| Ex-Dividend Date | n/a |
| Volume | 643 |
| Average Volume | 5,134 |
| Open | 95.26 |
| Previous Close | 95.02 |
| Day's Range | 95.26 - 97.62 |
| 52-Week Range | 84.86 - 109.51 |
| Beta | 0.67 |
| RSI | 47.92 |
| Earnings Date | Feb 4, 2026 |
About Boston Scientific
Boston Scientific Corporation develops, manufactures, and markets medical devices for use in various interventional medical specialties worldwide. It operates in two segments, MedSurg and Cardiovascular. The company offers devices to diagnose and treat a range of gastrointestinal conditions, such as resolution clips, biliary stent systems, stents and electrocautery enhanced delivery systems, direct visualization systems, digital catheters, and single-use duodenoscopes, as well as endoluminal surgery and infection prevention portfolios; devices ... [Read more]
Financial Performance
In 2024, Boston Scientific's revenue was $16.75 billion, an increase of 17.61% compared to the previous year's $14.24 billion. Earnings were $1.85 billion, an increase of 18.03%.
Financial numbers in USD Financial StatementsNews
How Is Boston Scientific's Cardiovascular Growth Path Shaping Up?
BSX's $50B cardiovascular business aims to outpace market growth across EP, WATCHMAN, ICTx and more.
BSX vs. RMD: Which Medical Device Stock Is the Stronger Play Now?
Boston Scientific edges out Resmed as WATCHMAN momentum, EP gains and acquisitions fuel stronger recent price performance in a growing medical device market.
Boston Scientific: Premium MedTech Growth Story With Attractive Valuation Upside
Boston Scientific: Gangbusters Growth, And A Valuation To Match
Boston Scientific Corporation is rated a Hold with double-digit revenue growth and margin expansion. Learn more about BSX stock here.
February 2026 Options Now Available For Boston Scientific (BSX)
Investors in Boston Scientific Corp. (Symbol: BSX) saw new options become available today, for the February 2026 expiration. At Stock Options Channel, our YieldBoost formula has looked up and down the...
How Well Is Boston Scientific Placed for Long-Term Endoscopy Growth?
BSX's Endoscopy unit targets an $8B market, spanning pancreaticobiliary, surgery and obesity, with plans to outgrow the market.
Here's How Much You Would Have Made Owning Boston Scientific Stock In The Last 5 Years
Boston Scientific (NYSE: BSX) has outperformed the market over the past 5 years by 9.85% on an annualized basis producing an average annual return of 22.84%. Currently, Boston Scientific has a market...
Decoding Boston Scientific's Options Activity: What's the Big Picture?
Whales with a lot of money to spend have taken a noticeably bearish stance on Boston Scientific . Looking at options history for Boston Scientific (NYSE: BSX) we detected 13 trades. If we consider th...
August 2026 Options Now Available For Boston Scientific (BSX)
Investors in Boston Scientific Corp. (Symbol: BSX) saw new options begin trading today, for the August 2026 expiration. One of the key data points that goes into the price an option buyer is willing t...
Boston Scientific Corp (BSX)'s Winning Formula: Financial Metrics and Competitive Strengths
Boston Scientific Corp (BSX)'s Winning Formula: Financial Metrics and Competitive Strengths
Boston Scientific's Global Expansion: What's Behind the Growth?
BSX expands globally with R&D, AI-driven manufacturing and Emerging Markets, aiming for $1B+ revenues in China in 2025.
Boston Scientific (BSX) Advances While Market Declines: Some Information for Investors
Boston Scientific (BSX) reached $94.48 at the closing of the latest trading day, reflecting a +1.65% change compared to its last close.
BSX: Canaccord Genuity Lowers Boston Scientific's Price Target | BSX Stock News
BSX: Canaccord Genuity Lowers Boston Scientific's Price Target | BSX Stock News
Is It Worth Investing in Boston Scientific (BSX) Based on Wall Street's Bullish Views?
According to the average brokerage recommendation (ABR), one should invest in Boston Scientific (BSX). It is debatable whether this highly sought-after metric is effective because Wall Street analysts...
Boston Scientific (BSX) Stock Falls Amid Market Uptick: What Investors Need to Know
The latest trading day saw Boston Scientific (BSX) settling at $91.75, representing a -1.02% change from its previous close.
Boston Scientific Sustains Momentum in the PFA Market: What's Next?
BSX builds momentum in PFA as FARAPULSE posts strong growth, and new trial results and expanded FDA labeling boost its AF treatment push.
A Look Into Boston Scientific Inc's Price Over Earnings
In the current market session, Boston Scientific Inc. (NYSE: BSX) share price is at $94.18, after a 0.36% increase. Moreover, over the past month, the stock decreased by 9.36% , but in the past year,...
If You Invested $1000 In Boston Scientific Stock 5 Years Ago, You Would Have This Much Today
Boston Scientific (NYSE: BSX) has outperformed the market over the past 5 years by 10.84% on an annualized basis producing an average annual return of 23.89%. Currently, Boston Scientific has a marke...
M&A Strategy Strengthens Boston Scientific's Growth Prospects
BSX accelerates growth as a wave of acquisitions boosts core portfolios and fuels expansion into high-growth adjacent markets.
Brianne Gardner's Top Picks: Constellation Energy, Microsoft & Boston Scientific
Brianne Gardner, portfolio manager & senior wealth manager at Velocity Investment Partners, Raymond James, shares her top stock picks to watch in the market.
Why Boston Scientific (BSX) is a Top Momentum Stock for the Long-Term
The Zacks Style Scores offers investors a way to easily find top-rated stocks based on their investing style. Here's why you should take advantage.
Is Boston Scientific (BSX) a Buy as Wall Street Analysts Look Optimistic?
According to the average brokerage recommendation (ABR), one should invest in Boston Scientific (BSX). It is debatable whether this highly sought-after metric is effective because Wall Street analysts...
Boston Scientific's Margins Strengthen in Q3: What's Driving It?
BSX posts stronger Q3 margins as growth in EP and WATCHMAN lifts product mix despite tariff pressure.
BSX vs. EW: Which Heart Device Stock Is the Smarter Investment Now?
Boston Scientific's EP breadth, WATCHMAN momentum and acquisitions give it an edge over Edwards in cardiovascular devices.